(International Print/Online Journal)

SJIF IMPACT FACTOR: 6.829
PUBMED-National Library of Medicine ID-101739732

ISSN (Print): 2209-2870
ISSN (Online): 2209-2862

International Journal of Medical Science and Current Research (IJMSCR)
Available online at: www.ijmscr.com
Volume 9, Issue1, Page No:600-611
January-February2026

IJMSCR

Role of Target Site Concentration in Pharmacokinetic Modelling: Bridging Systemic Exposure and Pharmacological Response

Saivishal Daripelli[1*],P R Anand Vijaya Kumar[2]
[1]Ph.D. Scholar, [2]Professor
Department of Pharmacology,
JSS College of Pharmacy, Ooty, Udhagamandalam - 643 001
Tamil Nadu, India

***Corresponding Author:**
Saivishal Daripelli
Department of Pharmacology, JSS College of Pharmacy, Ooty, Udhagamandalam - 643 001

Type of Publication: Review Article
Conflicts of Interest: Nil

Abstract

Pharmacokinetic (PK) modeling traditionally relies on plasma drug concentration data to characterize systemic exposure and support dose selection during drug development. However, the pharmacological response of a drug is ultimately determined by its concentration at the site of action rather than in systemic circulation. Discrepancies between plasma and tissue concentrations arise due to physiological barriers, tissue binding, transporter activity, and local metabolic processes. Consequently, plasma concentrations may not adequately reflect pharmacologically relevant exposure in many therapeutic areas. Over the past two decades, increasing attention has been directed toward incorporating target site drug concentrations into pharmacokinetic and pharmacodynamic modeling frameworks. Advances in experimental techniques, including microdialysis, imaging-based approaches, and tissue sampling methods, have enabled direct measurement of drug concentrations in extracellular tissue compartments. These measurements have improved understanding of tissue distribution kinetics and have facilitated the development of more mechanistic pharmacokinetic models. Integrating target site concentration data into pharmacokinetic models enhances prediction of pharmacodynamic responses, improves translational accuracy between preclinical and clinical studies, and supports model-informed drug development. This narrative review discusses the conceptual basis of target site pharmacokinetics, experimental approaches for measuring tissue concentrations, and modeling strategies used to integrate target site exposure into pharmacokinetic frameworks. Applications across therapeutic areas including central nervous system disorders, oncology, infectious diseases, and inflammatory conditions are discussed. Challenges associated with target site measurements and future directions in quantitative pharmacology are also highlighted.

Keywords: Pharmacokinetics, Simulations and Predictions, Microdialysis, Traget site concentration

Introduction

Pharmacokinetics (PK) is a cornerstone of drug discovery and development, describing the processes of absorption, distribution, metabolism, and elimination (ADME). Traditionally, PK analyses have relied heavily on plasma drug concentration data because blood sampling is relatively simple, minimally invasive, and reproducible across populations (1, 2). Plasma PK has therefore been widely used as a surrogate marker for predicting drug efficacy and safety.

However, the pharmacological activity of most drugs is determined not by plasma concentrations but by the concentration of the drug at its site of action within tissues. The principle of pharmacodynamics (PD) dictates that drug–receptor interactions occur locally,

and the magnitude of the pharmacological response depends on the drug concentration at that site. Plasma concentrations provide only an indirect estimate of systemic exposure and may not accurately represent drug concentrations in the extracellular fluid of target tissues (3).

Several physiological and biochemical factors contribute to discrepancies between plasma and tissue concentrations. These include:

1. **Tissue permeability:** Drugs must cross capillary membranes to reach tissues. Lipophilicity, molecular size, and ionization state influence permeability.
2. **Regional blood flow:** Highly perfused organs (e.g., liver, kidney) may achieve rapid equilibrium, whereas poorly perfused tissues (e.g., cartilage, tumors) may exhibit delayed distribution.
3. **Transporter activity:** Efflux and uptake transporters (e.g., P-glycoprotein at the BBB) can restrict or enhance tissue penetration (4).
4. **Protein binding:** Binding to plasma and tissue proteins alters free drug availability.
5. **Local metabolism:** Enzymatic activity within tissues can reduce effective concentrations.

These factors are particularly relevant in tissues protected by biological barriers. For example, the blood–brain barrier (BBB) restricts drug penetration into the central nervous system (CNS), making plasma concentrations an unreliable indicator of brain exposure (5). Similarly, tumor tissues often exhibit abnormal vascular architecture and increased interstitial pressure, which significantly affect drug distribution within the tumor microenvironment (6).

The limitations of plasma PK have prompted increasing interest in target site pharmacokinetics. Advances in experimental techniques, particularly microdialysis, have enabled direct measurement of unbound drug concentrations in tissue extracellular fluid. Because only the unbound fraction of a drug can diffuse across membranes and interact with biological targets, microdialysis provides valuable insight into pharmacologically relevant exposure (7).

The integration of target site concentration data into PK/PD and PBPK models has transformed modern drug development. By incorporating tissue-level exposure, researchers can better characterize drug distribution processes, capture temporal dissociation between systemic exposure and pharmacological response, and improve translational accuracy between preclinical and clinical studies (8, 9).

This review aims to provide a comprehensive overview of the role of target site concentration in pharmacokinetic modeling. We will discuss the conceptual framework, experimental techniques, modeling strategies, and applications across therapeutic areas. Case studies will illustrate how microdialysis and PBPK modeling have advanced our understanding of drug distribution. Finally, we will highlight challenges and future perspectives in this evolving field.

1. Conceptual Basis of Target Site Concentration

Target site concentration refers to the drug concentration at the specific biological location where the drug exerts its pharmacological effect. This site may be located within extracellular fluid, intracellular compartments, or membrane-bound receptor regions. The relationship between plasma concentration and target site concentration is governed by multiple physiological processes, and the time course of drug concentration in tissues may differ significantly from that observed in plasma (10).

1.1 Extracellular vs. Intracellular Concentrations

Drugs acting on extracellular receptors (e.g., neurotransmitter receptors) require sufficient concentrations in the interstitial fluid. Conversely, drugs targeting intracellular enzymes or nucleic acids must penetrate cell membranes, often requiring active transport or facilitated diffusion. Intracellular concentrations may be influenced by pH gradients, ion trapping, and organelle sequestration (11).

1.2 Bound vs. Unbound Drug

Only unbound drug molecules are pharmacologically active. Tissue binding can lead to drug accumulation, prolonging pharmacological effects even when plasma concentrations decline. For example, lipophilic drugs may accumulate in adipose tissue, creating a reservoir that slowly releases drug into circulation (12).

1.3 Biological Barriers

- **Blood–Brain Barrier (BBB):** Tight junctions and efflux transporters restrict CNS penetration. Drugs with poor BBB permeability may show high plasma levels but negligible brain exposure (13).

Volume 9, Issue 1;January-February2026; Page No 600-611

- **Tumor Microenvironment:** Abnormal vasculature, elevated interstitial pressure, and heterogeneous perfusion reduce drug penetration. This explains why plasma PK often overestimates tumor exposure (14).
- **Inflamed Tissues:** Inflammation increases vascular permeability and blood flow, enhancing drug penetration into synovial fluid or infected tissues (15).

1.4 Temporal Dissociation

Drug concentrations at the target site may lag behind plasma concentrations due to distribution kinetics. This temporal dissociation is critical for PK-PD modeling, as pharmacological effects often correlate more closely with tissue concentrations than with plasma levels (16).

1.5 Clinical Implications

Understanding target site PK is essential for:

- **Dose optimization:** Ensuring adequate tissue exposure without toxicity.
- **Drug development:** Identifying compounds with favorable distribution profiles.
- **Personalized medicine:** Accounting for patient-specific factors (e.g., transporter polymorphisms, disease-modified physiology).

2. Experimental Techniques for Measuring Target Site Concentration

Understanding drug concentrations at the site of action requires specialized experimental techniques. Plasma sampling alone cannot capture the complexity of tissue distribution, so researchers have developed methods to directly or indirectly quantify drug levels in tissues. Each technique has unique strengths and limitations, and their integration into pharmacokinetic modeling has advanced the field considerably.

2.1 Microdialysis

Microdialysis is widely regarded as the gold standard for measuring unbound drug concentrations in extracellular fluid. A probe with a semi-permeable membrane is inserted into the tissue of interest, allowing small molecules to diffuse into a perfusion fluid that is subsequently analyzed (17).

Advantages:

1. Measures pharmacologically active unbound drug fraction.
2. Provides continuous sampling over time.
3. Applicable to diverse tissues (brain, muscle, tumors, synovial fluid).

Limitations:

1. Invasive procedure requiring probe implantation.
2. Recovery efficiency depends on probe calibration.
3. Ethical constraints limit use in humans.

Microdialysis has been instrumental in CNS drug development, where BBB penetration is critical. For example, studies with antiepileptic drugs demonstrated that brain extracellular fluid concentrations correlate more closely with therapeutic effects than plasma levels (18).

2.2 Tissue Homogenization

Traditional tissue distribution studies involve collecting tissue samples, homogenizing them, and quantifying drug content. While this provides total drug concentration, it does not distinguish between bound and unbound fractions (19).

Advantages:

1. Straightforward methodology.
2. Provides absolute tissue drug content.

Limitations:

1. Overestimates pharmacologically relevant exposure.
2. Requires invasive tissue collection.
3. Cannot capture temporal dynamics.

Despite limitations, homogenization remains useful in preclinical studies for assessing tissue accumulation and distribution patterns.

2.3 Imaging-Based Techniques

Non-invasive imaging methods such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) allow visualization of drug distribution in vivo (20). Radiolabeled drugs can be tracked, providing spatial and temporal information about tissue penetration.

Advantages:

1. Non-invasive and repeatable in humans.
2. Provides whole-body distribution data.

Limitations:

Volume 9, Issue 1;January-February2026; Page No 600-611

1. Requires radiolabeling, which may alter drug properties.
2. Limited resolution for small tissue compartments.

PET imaging has been particularly valuable in oncology, where radiolabeled chemotherapeutics reveal heterogeneous tumor penetration (21).

2.4 Emerging Biosensors

Recent advances in nanotechnology and biosensor development promise minimally invasive, real-time monitoring of tissue drug concentrations (22). Implantable sensors capable of detecting unbound drug molecules could revolutionize clinical pharmacokinetics by providing continuous data streams.

Figure 1: Conceptual framework illustrating the role of target site concentration in pharmacokinetic modelling



3. Integration of Target Site Concentration into Pharmacokinetic Models

The incorporation of tissue concentration data into pharmacokinetic models has led to more mechanistic

Volume 9, Issue 1;January-February2026; Page No 600-611

approaches that better capture drug distribution and pharmacological effects.

3.1 Effect Compartment Models

Effect compartment models introduce a hypothetical compartment representing the biophase where drug–receptor interactions occur. The concentration in this compartment drives pharmacological response, accounting for delays between plasma exposure and effect (23).

3.2 Intercompartmental Clearance Models

These models explicitly describe drug transfer between plasma and tissue compartments using clearance parameters. They capture bidirectional exchange and allow simulation of tissue accumulation or restricted penetration (24).

3.3 Receptor-Binding Models

Advanced models incorporate receptor binding kinetics, target turnover, and drug–target complex dynamics. These mechanistic frameworks provide deeper insights into pharmacodynamics, particularly for biologics and targeted therapies (25).

3.4 Systems Pharmacology Approaches

Systems pharmacology integrates PK/PD with network biology, capturing interactions across multiple pathways. Incorporating tissue-level data enhances predictive accuracy for complex diseases such as cancer and neurodegeneration (26).

4. Pharmacokinetic–Pharmacodynamic (PK–PD) Modeling

PK–PD modeling links drug exposure to pharmacological response. Traditional models often rely on plasma concentrations, but incorporating target site concentrations significantly improves predictive accuracy.

4.1 Traditional PK-PD Models

These models assume plasma concentration drives pharmacological effect. While useful, they fail to capture delays or discrepancies caused by tissue distribution (27).

4.2 Target Site–Driven PK–PD Models

By integrating tissue concentration data, models can more accurately predict onset, intensity, and duration of drug effects. For example, antibiotics show better correlation between tissue concentrations and bacterial kill rates than plasma levels (28).

4.3 Case Examples

- **CNS Drugs:** Brain extracellular fluid concentrations measured via microdialysis correlate with seizure control in epilepsy models (29).
- **Oncology:** Tumor tissue concentrations predict therapeutic response more reliably than plasma PK (30).
- **Anti-Inflammatory Drugs:** Synovial fluid concentrations explain prolonged efficacy despite declining plasma levels (31).

4.4 Translational Modeling

Incorporating target site PK into translational models bridges preclinical and clinical studies. This improves dose selection, reduces attrition, and enhances patient outcomes (32). The comparison of plasma-driven and target site-driven PK-PD models is represented in Table 1.

Table 1: Comparison of plasma-driven vs. target site-driven PK-PD models.

Feature	Plasma-driven PK-PD	Target site-driven PK–PD
Driving concentration	Plasma	Tissue extracellular fluid
Accuracy	Moderate	High
Delay capture	Limited	Explicit
Translational relevance	Lower	Higher
Applications	General PK–PD	CNS, oncology, anti-infective

Volume 9, Issue 1;January-February2026; Page No 600-611

5. Role in Physiologically Based Pharmacokinetic (PBPK) Modeling

Physiologically based pharmacokinetic (PBPK) models provide a mechanistic framework for predicting drug distribution across organs and tissues. These models incorporate anatomical and physiological parameters such as organ volumes, blood flow rates, and membrane permeability. Traditionally, PBPK models have relied on plasma concentration data for validation, but the inclusion of target site concentration data significantly enhances their predictive accuracy (33).

5.1 Structure of PBPK Models

PBPK models are compartmental representations of the body, with each compartment corresponding to a specific organ or tissue. Drug distribution is modeled based on physiological parameters and physicochemical properties of the drug. Incorporating tissue-level data allows for more accurate simulation of drug penetration into restricted compartments such as the brain or tumors (33).

5.2 Validation with Tissue Data

Target site concentration data obtained from microdialysis or imaging studies provide critical validation points for PBPK models. For example, CNS PBPK models incorporating microdialysis-derived brain extracellular fluid concentrations have improved predictions of antiepileptic drug exposure (34).

5.3 Applications in CNS and Oncology

- **CNS Drugs:** PBPK models incorporating BBB permeability and transporter activity predict brain exposure more accurately than plasma-based models (32).
- **Oncology:** Tumor-specific PBPK models account for abnormal vasculature and interstitial pressure, improving simulation of chemotherapeutic distribution (30).

6. Applications in Drug Development

Target site pharmacokinetics has broad applications across therapeutic areas. By integrating tissue-level data, drug developers can optimize dosing strategies, improve translational accuracy, and reduce attrition rates.

6.1 Central Nervous System (CNS) Drugs

Drug development for CNS disorders faces challenges related to limited brain penetration. Plasma concentrations often fail to predict therapeutic efficacy. Microdialysis studies have shown that unbound brain extracellular fluid concentrations correlate more closely with pharmacological activity (34). Incorporating these data into PBPK models enhances dose optimization for antiepileptic and antidepressant drugs.

6.2 Oncology

Tumor tissues exhibit complex microenvironments that influence drug penetration. Plasma PK often overestimates tumor exposure due to restricted vascular permeability and elevated interstitial pressure (30). Microdialysis measurements of chemotherapeutics such as doxorubicin have revealed substantial variability in tumor penetration across patients, explaining differences in treatment outcomes (14).

6.3 Anti-Infective Therapy

For antimicrobial drugs, relevant exposure occurs at the site of infection rather than in plasma. Lung tissue concentrations are more predictive of efficacy in pulmonary infections, while synovial fluid concentrations are critical in joint infections (7). Microdialysis-informed PBPK models have improved antibiotic dosing strategies in critically ill patients.

6.4 Inflammatory Diseases

Drug distribution into inflamed tissues such as synovial fluid determines therapeutic efficacy for anti-inflammatory drugs. Microdialysis studies with diclofenac demonstrated prolonged tissue accumulation, explaining sustained pharmacological activity despite declining plasma levels (8).

6.5 Personalized Medicine

Target site PK supports personalized dosing by accounting for patient-specific factors such as transporter polymorphisms, disease-modified physiology, and co-morbidities. Integrating tissue-level data into PBPK models enables individualized therapy (17). Applications of target site pharmacokinetics across therapeutic areas are represented in Table 2.

Volume 9, Issue 1;January-February2026; Page No 600-611

Table 2: Applications of target site pharmacokinetics across therapeutic areas.

Therapeutic Area	Challenge	Role of Target Site PK	Outcome
CNS	BBB restricts penetration	Brain extracellular fluid measurement	Improved dose optimization
Oncology	Tumor microenvironment	Tumor microdialysis	Better prediction of treatment outcomes
Anti-infective	Site-specific infection	Tissue-level antibiotic PK	Enhanced efficacy
Inflammatory	Tissue binding, inflammation	Synovial fluid PK	Prolonged activity
Personalized medicine	Patient variability	PBPK with tissue data	Individualized dosing

7. Case Studies Demonstrating Target Site PK

Case studies illustrate the practical utility of target site pharmacokinetics in drug development.

Case Study 1: Antibiotic Target Site Exposure in Soft Tissue Infections

Microdialysis studies with cefpirome and cefodizime revealed that tissue concentrations were 20-40% lower than plasma levels, highlighting the limitations of plasma PK (35). PBPK models incorporating these data improved predictions of antibiotic distribution in infected tissues, guiding dose optimization.

Case Study 2: Brain Microdialysis for CNS Drug Distribution

Carbamazepine, an antiepileptic drug, was studied using brain microdialysis. Results showed that unbound brain extracellular fluid concentrations correlated with seizure control, while plasma levels did not (36). Incorporating these data into PBPK models improved translational accuracy.

Case Study 3: Tumor Microdialysis in Oncology

Doxorubicin penetration into tumor tissues was assessed using microdialysis. Tumor extracellular concentrations were substantially lower than plasma levels due to restricted vascular permeability (37). Variability across patients explained differences in treatment outcomes, supporting individualized dosing strategies.

Case Study 4: Synovial Microdialysis in Anti-Inflammatory Drug Research

Diclofenac distribution into synovial fluid was studied using microdialysis. Results showed prolonged tissue accumulation, explaining sustained pharmacological activity despite declining plasma concentrations (38). PBPK models incorporating synovial tissue compartments refined dosing intervals. The Table 3 represents summary of case studies for target site pharmacokinetics.

Table 3: Summary of case studies demonstrating target site pharmacokinetics

Case Study	Drug	Target Site	Key Findings
Soft tissue infections	Cefpirome, Cefodizime	Skeletal muscle, subcutaneous tissue	Tissue concentrations 20–40% lower than plasma
CNS drug distribution	Carbamazepine	Brain extracellular fluid	Brain concentrations correlated with efficacy
Oncology	Doxorubicin	Tumor extracellular fluid	Tumor penetration highly variable

Volume 9, Issue 1;January-February2026; Page No 600-611

Anti-inflammatory	Diclofenac	Synovial fluid	Tissue accumulation prolonged activity

8. Challenges and Limitations

Despite the clear advantages of measuring target site concentrations, several challenges remain that limit widespread adoption in clinical pharmacology.

8.1 Technical Complexity

Microdialysis requires surgical implantation of probes, which can be technically demanding and invasive. Probe calibration and recovery efficiency must be carefully validated to ensure accurate measurements (5). Imaging-based techniques, while non-invasive, require radiolabeling that may alter drug properties.

8.2 Ethical Considerations

Human studies involving invasive tissue sampling raise ethical concerns. Microdialysis in the brain or tumors is limited to specific clinical contexts, such as neurosurgery or oncology trials, where sampling can be justified (36).

8.3 Translational Challenges

Species differences in physiology and drug metabolism complicate extrapolation from animal models to humans. For example, transporter expression at the BBB varies across species, affecting CNS penetration (39).

8.4 Regulatory Barriers

Regulatory agencies have traditionally relied on plasma PK for dose selection. Incorporating tissue-level data into regulatory submissions requires standardized methodologies and validation frameworks (40).

8.5 Data Integration

Integrating heterogeneous data from microdialysis, imaging, and biosensors into PK/PD models is complex. Harmonization of methodologies and computational approaches is needed to ensure consistency (41).

9. Future Perspectives

Advances in technology and computational modeling promise to overcome current limitations and expand the role of target site pharmacokinetics.

9.1 Biosensors and Nanotechnology

Implantable biosensors capable of real-time monitoring of unbound drug concentrations could revolutionize clinical pharmacokinetics. Nanotechnology-based sensors may provide minimally invasive, continuous data streams (42).

9.2 Artificial Intelligence (AI) and Machine Learning

AI-assisted modeling can integrate complex datasets from plasma, tissue, imaging, and genomics. Machine learning algorithms can identify patterns and predict tissue distribution, enhancing model-informed drug development (43).

9.3 Systems Pharmacology

Systems pharmacology integrates PK/PD with network biology, capturing drug effects across multiple pathways. Incorporating tissue-level data enhances predictive accuracy for complex diseases such as cancer and neurodegeneration (44).

9.4 Personalized Medicine

Target site PK supports individualized dosing by accounting for patient-specific factors such as transporter polymorphisms, co-morbidities, and disease-modified physiology. PBPK models incorporating tissue data enable precision medicine approaches (45).

9.5 Regulatory Evolution

Regulatory agencies are increasingly recognizing the value of model-informed drug development. Incorporating target site PK into regulatory frameworks will improve dose selection and therapeutic outcomes (46).

10. Conclusion

Accurate characterization of drug concentrations at pharmacological target sites is essential for understanding therapeutic efficacy and safety. Plasma pharmacokinetics, while valuable for systemic exposure, often fails to reflect drug levels in tissues where pharmacological effects occur. Microdialysis, imaging, and tissue sampling provide direct measurements of tissue concentrations, enabling

Volume 9, Issue 1;January-February2026; Page No 600-611

integration into PK/PD and PBPK models. These approaches improve prediction of therapeutic response, enhance translational accuracy, and support model-informed drug development.

Applications across CNS disorders, oncology, infectious diseases, and inflammatory conditions demonstrate the utility of target site PK. Case studies highlight how microdialysis-informed PBPK models optimize dosing strategies and explain variability in treatment outcomes. Challenges remain, including technical complexity, ethical constraints, and translational barriers. However, advances in biosensors, AI-assisted modeling, and systems pharmacology promise to overcome these limitations. Incorporating target site PK into regulatory frameworks will further enhance drug development efficiency and patient outcomes.

Ultimately, bridging systemic exposure and pharmacological response through target site pharmacokinetics represents a paradigm shift in quantitative pharmacology. Continued innovation in experimental techniques and modeling methodologies will ensure that drug development becomes more precise, predictive, and patient-centered.

References

1. Derendorf H, Hochhaus G, Meibohm B, Möllmann H, Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998 Apr;101(4 Pt 2):S440-6. doi: 10.1016/s0091-6749(98)70156-3.
2. Mager DE, Jusko WJ. Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2008 Jun;83(6):909-12. doi: 10.1038/clpt.2008.52.
3. Müller M. Science, medicine, and the future: Microdialysis. BMJ. 2002 Mar 9;324(7337):588-91. doi: 10.1136/bmj.324.7337.588.
4. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci. 2008 Apr;29(4):186-91. doi: 10.1016/j.tips.2008.01.007.
5. de Lange EC, Danhof M, de Boer AG, Breimer DD. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Brain Res Rev. 1997 Sep 30;25(1):27-49. doi: 10.1016/s0165-0173(97)00014-3.
6. Chien JY, Friedrich S, Heathman MA, de Alwis DP, Sinha V. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J. 2005 Oct 7;7(3):E544-59. doi: 10.1208/aapsj070355.
7. Müller M, Schmid R, Georgopoulos A, Buxbaum A, Wasicek C, Eichler HG. Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther. 1995 Apr;57(4):371-80. doi: 10.1016/0009-9236(95)90205-8.
8. Elmquist WF, Sawchuk RJ. Application of microdialysis in pharmacokinetic studies. Pharm Res. 1997 Mar;14(3):267-88. doi: 10.1023/a:1012081501464.
9. Yamamoto Y, Danhof M, de Lange ECM. Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations. AAPS J. 2017 Jul;19(4):891-909. doi: 10.1208/s12248-017-0050-3.
10. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. 4th ed. CRC Press; 2016.
11. Jusko WJ. Moving from basic toward systems pharmacodynamic models. J Pharm Sci. 2013 Sep;102(9):2930-40. doi: 10.1002/jps.23590.
12. Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol. 2013 Aug 14;2(8):e63. doi: 10.1038/psp.2013.41.
13. de Lange EC, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet. 2002;41(10):691-703. doi: 10.2165/00003088-200241100-00001.
14. Blakeley J, Portnow J. Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development. Expert Opin

Volume 9, Issue 1;January-February2026; Page No 600-611

Drug Metab Toxicol. 2010 Dec;6(12):1477-91. doi: 10.1517/17425255.2010.523420.

15. Toutain PL, del Castillo JRE, P.L Toutain, J.R.E del Castillo, A Bousquet-Mélo. The pharmacokinetic–pharmacodynamic approach to a rational dosage regimen for antibiotics. Research in Veterinary Science. 2002; 73(2):105-114. https://doi.org/10.1016/S0034-5288(02)00039-5.
16. Hammarlund-Udenaes, M. (2010), Active-Site Concentrations of Chemicals – Are They a Better Predictor of Effect than Plasma/Organ/Tissue Concentrations?. Basic & Clinical Pharmacology & Toxicology, 106: 215-220. https://doi.org/10.1111/j.1742-7843.2009.00517.x
17. Joukhadar C, Müller M. Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet. 2005;44(9):895-913. doi: 10.2165/00003088-200544090-00002.
18. Bungay PM, Morrison PF, Dedrick RL. Steady-state theory for quantitative microdialysis of solutes and water in vivo. Life Sci. 1990;46(2):105–119.
19. Ståhle L. Microdialysis in pharmacokinetics. Eur J Drug Metab Pharmacokinet. 1993 Jan-Mar;18(1):89-96. doi: 10.1007/BF03220011.
20. Zhuang L, Xia H, Gu Y, Derendorf H, Li Y, Liu C. Theory and Application of Microdialysis in Pharmacokinetic Studies. Curr Drug Metab. 2015;16(10):919-31. doi: 10.2174/1389200216666150812124109.
21. Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther. 2008 May;325(2):349-56. doi: 10.1124/jpet.107.130294.
22. Hammarlund-Udenaes M. The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev. 2000 Dec 15;45(2-3):283-94. doi: 10.1016/s0169-409x(00)00109-5.
23. Rowland M, Thomas NT. Clinical Pharmacokinetics: Concepts and Applications, 4e. Lippincott Williams & Wilkins; 2011. Accessed March 09, 2026.
24. Holford NG. Pharmacokinetics & Pharmacodynamics: Rational Dosing & the Time Course of Drug Action. In: Katzung BG, Vanderah TW. eds. Basic & Clinical Pharmacology, 15e. McGraw-Hill; 2021.
25. Bonate PL. Pharmacokinetic–Pharmacodynamic Modeling and Simulation. 2nd ed. Springer; 2011.
26. EFPIA MID3 Workgroup; Marshall SF, Burghaus R, Cosson V, Cheung SY, Chenel M, DellaPasqua O, Frey N, Hamrén B, Harnisch L, Ivanow F, Kerbusch T, Lippert J, Milligan PA, Rohou S, Staab A, Steimer JL, Tornøe C, Visser SA. Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation. CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):93-122. doi: 10.1002/psp4.12049.
27. Jusko WJ. Moving from basic toward systems pharmacodynamic models. J Pharm Sci. 2013 Sep;102(9):2930-40. doi: 10.1002/jps.23590.
28. Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):195-209. doi: 10.1111/j.1742-7843.2009.00513.x.
29. Zestos AG, Luna-Munguia H, Stacey WC, Kennedy RT. Use and Future Prospects of in Vivo Microdialysis for Epilepsy Studies. ACS Chem Neurosci. 2019 Apr 17;10(4):1875-1883. doi: 10.1021/acschemneuro.8b00271.
30. Kun Mi, Wei-Chun Chou, Qiran Chen, Long Yuan, Venkata N. Kamineni, Yashas Kuchimanchi, Chunla He, Nancy A. Monteiro-Riviere, Jim E. Riviere, Zhoumeng Lin. Predicting tissue distribution and tumor delivery of nanoparticles in mice using machine learning models. Journal of Controlled Release. 2024; 374: 219-229. https://doi.org/10.1016/j.jconrel.2024.08.015.
31. Wallis WJ, Simkin PA. Antirheumatic drug concentrations in human synovial fluid and synovial tissue. Observations on extravascular pharmacokinetics. Clin Pharmacokinet. 1983 Nov-

Volume 9, Issue 1;January-February2026; Page No 600-611

Dec;8(6):496-522. doi: 10.2165/00003088-198308060-00002.

32. Duffull SB, Wright DF, Winter HR. Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint. Br J Clin Pharmacol. 2011 Jun;71(6):807-14. doi: 10.1111/j.1365-2125.2010.03891.x.

33. van der Graaf PH, Benson N. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res. 2011 Jul;28(7):1460-4. https://doi.org/10.1007/s11095-011-0467-9

34. Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro–in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012;92(1):50–61. https://doi.org/10.1038/clpt.2012.65

35. Müller M, Rohde B, Kovar A, Georgopoulos A, Eichler HG, Derendorf H. Relationship between serum and free interstitial concentrations of cefodizime and cefpirome in muscle and subcutaneous adipose tissue of healthy volunteers measured by microdialysis. J Clin Pharmacol. 1997 Dec;37(12):1108-13. doi: 10.1002/j.1552-4604.1997.tb04294.x.

36. Scheyer RD, During MJ, Spencer DD, Cramer JA, Mattson RH. Measurement of carbamazepine and carbamazepine epoxide in the human brain using in vivo microdialysis. Neurology. 1994 Aug;44(8):1469-72. doi: 10.1212/wnl.44.8.1469.

37. Jørgensen AR, Bue M, Hanberg P, Petersen EK, Harlev C, Hansen J, Baad-Hansen T, Safwat A, Stilling M. Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study. Cancer Chemother Pharmacol. 2024 Jun;93(6):555-564. doi: 10.1007/s00280-023-04637-1.

38. Burian, A., Frangione, V., Rovati, S., Mautone, G., Leuratti, C., Vaccani, A., Crevenna, R., Keilani, M., Burian, B., Brunner, M. and Zeitlinger, M. (2013), Prostaglandin level after topical diclofenac. Br J Clin Pharmacol, 76: 880-887. https://doi.org/10.1111/bcp.12125

39. Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. CPT Pharmacometrics Syst Pharmacol. 2012;1(9):e1. https://doi.org/10.1038/clpt.2010.298.

40. Grimstein, Manuela et al. Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology. Journal of Pharmaceutical Sciences, Volume 108, Issue 1, 21 - 25. https://doi.org/10.1016/j.xphs.2018.10.033

41. Deepika D, Kumar V. The Role of "Physiologically Based Pharmacokinetic Model (PBPK)" New Approach Methodology (NAM) in Pharmaceuticals and Environmental Chemical Risk Assessment. International Journal of Environmental Research and Public Health. 2023; 20(4):3473. https://doi.org/10.3390/ijerph20043473

42. Wu, Z., Qiao, Z., Chen, S. et al. Interstitial fluid-based wearable biosensors for minimally invasive healthcare and biomedical applications. Commun Mater 5, 33 (2024). https://doi.org/10.1038/s43246-024-00468-6

43. Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics. 2023 Jul 10;15(7):1916. doi: 10.3390/pharmaceutics15071916.

44. Bi X, Wang Y, Wang J, Liu C. Machine Learning for Multi-Target Drug Discovery: Challenges and Opportunities in Systems Pharmacology. Pharmaceutics. 2025 Sep 12;17(9):1186. doi: 10.3390/pharmaceutics17091186.

45. Hartmanshenn C, Scherholz M, Androulakis IP. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. J Pharmacokinet Pharmacodyn. 2016 Oct;43(5):481-504. doi: 10.1007/s10928-016-9492-y.

46. Mohammed S. Alasmari, Salwa Albusaysi, Marwa Elhefnawy, Ali M. Ali, Khalid Altigani, Mohammed Almoslem, Mohammed Alharbi, Jahad Alghamdi, Abdullah Alsultan. Model-

Volume 9, Issue 1;January-February2026; Page No 600-611

informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region. Saudi Pharmaceutical Journal. 2024; 32(12); 102207. https://doi.org/10.1016/j.jsps.2024.102207.

Volume 9, Issue 1;January-February2026; Page No 600-611